<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Kim H</submitter><funding>National Mango Board. RHD is supported by P01</funding><funding>NCRR NIH HHS</funding><funding>NIEHS NIH HHS</funding><funding>National Cancer Institute</funding><funding>NCI NIH HHS</funding><funding>NIH HHS</funding><pagination>1912-23</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC5026564</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>60(9)</volume><pubmed_abstract>&lt;h4>Scope&lt;/h4>Tannin-rich fruits have been evaluated as alternative prevention strategies for colorectal cancer based on their anti-inflammatory properties. This study compared tannin-rich preparations from mango (rich in gallotannins) and pomegranate (rich in ellagitannins) in the dextran sodium sulfate-induced colitis model.&lt;h4>Methods and results&lt;/h4>In rats, mango and pomegranate beverages decreased intestinal inflammation and the levels of pro-inflammatory cytokines in mucosa and serum. The mango beverage suppressed the ratio of phosphorylated/total protein expression of the IGF-1R-AKT/mTOR axis and downregulated mRNA expression of Igf1, Insr, and pik3cv. Pomegranate decreased p70S6K and RPS6, as well as Rps6ka2, Map2k2, and Mapk1 mRNA. In silico modeling indicated a high binding of d</pubmed_abstract><journal>Molecular nutrition &amp; food research</journal><pubmed_title>Comparison of anti-inflammatory mechanisms of mango (Mangifera Indica L.) and pomegranate (Punica Granatum L.) in a preclinical model of colitis.</pubmed_title><pmcid>PMC5026564</pmcid><funding_grant_id>CA090890</funding_grant_id><funding_grant_id>ES023512</funding_grant_id><funding_grant_id>T32 RR031229</funding_grant_id><funding_grant_id>T32 OD011083</funding_grant_id><funding_grant_id>P30 ES023512</funding_grant_id><funding_grant_id>P01 CA090890</funding_grant_id><pubmed_authors>Mertens-Talcott SU</pubmed_authors><pubmed_authors>Dashwood RH</pubmed_authors><pubmed_authors>Pfent CM</pubmed_authors><pubmed_authors>Bisson WH</pubmed_authors><pubmed_authors>Kim H</pubmed_authors><pubmed_authors>Talcott ST</pubmed_authors><pubmed_authors>Ivanov I</pubmed_authors><pubmed_authors>Prudhomme KR</pubmed_authors><pubmed_authors>Banerjee N</pubmed_authors></additional><is_claimable>false</is_claimable><name>Comparison of anti-inflammatory mechanisms of mango (Mangifera Indica L.) and pomegranate (Punica Granatum L.) in a preclinical model of colitis.</name><description>&lt;h4>Scope&lt;/h4>Tannin-rich fruits have been evaluated as alternative prevention strategies for colorectal cancer based on their anti-inflammatory properties. This study compared tannin-rich preparations from mango (rich in gallotannins) and pomegranate (rich in ellagitannins) in the dextran sodium sulfate-induced colitis model.&lt;h4>Methods and results&lt;/h4>In rats, mango and pomegranate beverages decreased intestinal inflammation and the levels of pro-inflammatory cytokines in mucosa and serum. The mango beverage suppressed the ratio of phosphorylated/total protein expression of the IGF-1R-AKT/mTOR axis and downregulated mRNA expression of Igf1, Insr, and pik3cv. Pomegranate decreased p70S6K and RPS6, as well as Rps6ka2, Map2k2, and Mapk1 mRNA. In silico modeling indicated a high binding of d</description><dates><release>2016-01-01T00:00:00Z</release><publication>2016 Sep</publication><modification>2025-06-01T02:50:09.002Z</modification><creation>2025-06-01T02:50:09.002Z</creation></dates><accession>S-EPMC5026564</accession><cross_references><pubmed>27028006</pubmed><doi>10.1002/mnfr.201501008</doi></cross_references></HashMap>